ES2935596T3 - Compuesto de carbamato para prevenir o tratar la fibromialgia - Google Patents

Compuesto de carbamato para prevenir o tratar la fibromialgia Download PDF

Info

Publication number
ES2935596T3
ES2935596T3 ES17799675T ES17799675T ES2935596T3 ES 2935596 T3 ES2935596 T3 ES 2935596T3 ES 17799675 T ES17799675 T ES 17799675T ES 17799675 T ES17799675 T ES 17799675T ES 2935596 T3 ES2935596 T3 ES 2935596T3
Authority
ES
Spain
Prior art keywords
fibromyalgia
compound
pharmaceutical composition
formula
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17799675T
Other languages
English (en)
Spanish (es)
Inventor
Min Jae Jo
Han Ju Yi
Sun Gwan Hwang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2935596T3 publication Critical patent/ES2935596T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES17799675T 2016-05-19 2017-05-18 Compuesto de carbamato para prevenir o tratar la fibromialgia Active ES2935596T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
ES2935596T3 true ES2935596T3 (es) 2023-03-08

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17799675T Active ES2935596T3 (es) 2016-05-19 2017-05-18 Compuesto de carbamato para prevenir o tratar la fibromialgia

Country Status (13)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EP3711757B1 (en) * 2017-11-14 2025-05-07 SK Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
RU2299729C2 (ru) * 2001-07-16 2007-05-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
AU2009348523B2 (en) * 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome

Also Published As

Publication number Publication date
PL3459543T3 (pl) 2023-04-11
EP3459543B1 (en) 2022-12-21
US20190298694A1 (en) 2019-10-03
MX394245B (es) 2025-03-19
BR112018073553A2 (pt) 2019-03-19
CN109475529A (zh) 2019-03-15
RU2018144785A (ru) 2020-06-19
EP3459543A4 (en) 2020-01-15
KR102489052B1 (ko) 2023-01-16
DK3459543T3 (da) 2023-02-13
CA3024286A1 (en) 2017-11-23
WO2017200318A1 (ko) 2017-11-23
MX2018014080A (es) 2019-04-04
US10849882B2 (en) 2020-12-01
JP7071287B2 (ja) 2022-05-18
RU2753525C2 (ru) 2021-08-17
CN109475529B (zh) 2022-02-22
RU2018144785A3 (enExample) 2020-08-11
AU2017265839B2 (en) 2022-10-27
AU2017265839A1 (en) 2018-12-13
KR20170131242A (ko) 2017-11-29
EP3459543A1 (en) 2019-03-27
JP2019516707A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
US10849882B2 (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US20220087976A1 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
US20200268711A1 (en) Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
ES3054693T3 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
CA3024286C (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
ES3039979T3 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
BR112018073556B1 (pt) Uso de um composto de carbamato